默沙东 CEO 称，700 亿美元的新药预测尚未计入积极临床数据及 Terns 交易、PD-1/VEGF 双抗等新资产的增量。
默沙东 CEO Robert Davis 表示，其 1 月份给出的到 2030 年代中期新药组合 700 亿美元的预测，尚未计入积极临床试验结果以及 Terns Pharma 交易和一款实验性 PD-1/VEGF 双特异性抗体药物等其他新资产的潜在影响。原文 (en)
Merck CEO Robert Davis said its January forecast of $70 billion by the mid-2030s for its emerging portfolio of new medicines had not factored in the potential impact of positive clinical trial readouts and some other new assets, such as its Terns Pharma deal and an experimental PD-1/VEGF bispecific antibody drug.